Drugs / EU-Lantus®
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02059174 | Feb 2014 → Mar 2015 | type 1 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06627478 Comparator | Oct 2024 → Jul 2025 | — | Xentria, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EU-Lantus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06627478 ↗ |
| Route | Subcutaneous | “EU-Lantus™ 0.4 units/kg administered subcutaneously” NCT02059174 ↗ |